Refer the patient for in-lab polysomnography
The next best step is to refer this patient for in-laboratory polysomnography (PSG). The in-home sleep test showing fewer than 3 events per hour is inadequate and does not rule out obstructive sleep apnea (OSA) in this high-risk patient with significant clinical features and comorbidities.
Clinical Reasoning
This patient presents with a classic constellation of findings highly suggestive of moderate-to-severe OSA:
- High Epworth Sleepiness Scale score of 16 (severe excessive daytime sleepiness, normal <10)
- Witnessed apneas and loud snoring (partner-reported breathing pauses)
- Obesity with BMI 36 (major risk factor)
- Hypertension (diagnosed condition)
- Atrial fibrillation (irregularly irregular pulse on exam)
According to the 2017 American Academy of Sleep Medicine guidelines, when home sleep apnea testing (HSAT) yields negative or inadequate results despite high clinical suspicion, in-laboratory PSG is mandated 1. The guideline's clinical algorithm explicitly states: when HSAT does not provide a positive diagnosis or adequate results, the next step is to "perform PSG when OSA has not yet been ruled out" 1.
Why HSAT Failed Here
The in-home test showing <3 events/hour is likely a false negative due to:
- Technical inadequacy (may not have captured sufficient sleep time or data quality)
- Patient sleeping in an atypical position
- Equipment malfunction or sensor displacement
- The test may not have encompassed the patient's habitual sleep period
The AASM guideline specifies that a technically adequate HSAT requires "a minimum of 4 hours of technically adequate oximetry and flow data, obtained during a recording attempt that encompasses the habitual sleep period" 1. If these criteria aren't met, the study is inadequate.
Critical Comorbidity Considerations
This patient's atrial fibrillation is particularly important. OSA is present in 21-74% of AF patients, and untreated OSA significantly impacts AF management and outcomes 2. The relationship between OSA and cardiovascular disease, especially AF, is well-established 3. His irregularly irregular pulse confirms uncontrolled AF, which may be exacerbated by undiagnosed OSA 4.
Why Other Options Are Incorrect
Pregabalin: This is used for restless legs syndrome. The patient explicitly denies uncomfortable leg sensations and nocturnal walking, making this diagnosis unlikely and treatment inappropriate.
Automatic positive airway pressure device: You cannot prescribe PAP therapy without a confirmed OSA diagnosis. The negative HSAT does not establish the diagnosis, and empiric treatment would be inappropriate and potentially harmful.
No further testing: This would be dangerous given the high clinical suspicion, significant symptoms (ESS 16), witnessed apneas, and cardiovascular comorbidities. The negative HSAT is discordant with the clinical picture and must be investigated further.
Common Pitfalls to Avoid
Do not accept a negative HSAT at face value when clinical suspicion is high—the test has limitations and can miss OSA, particularly in patients with positional OSA or technical recording issues.
Do not ignore the cardiovascular implications—this patient's AF, hypertension, and obesity create a high-risk phenotype where untreated OSA significantly worsens outcomes 5.
Do not delay diagnosis—the patient is on apixaban for AF, has hypertension on an ARB, and hyperlipidemia on a statin. Confirming and treating OSA could improve blood pressure control, reduce AF burden, and decrease cardiovascular risk 2, 3.
The in-laboratory PSG will provide comprehensive monitoring including EEG (to confirm sleep stages), respiratory effort, oxygen saturation, and cardiac rhythm throughout the night, giving a definitive diagnosis and severity assessment to guide appropriate treatment.